Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for
EGFR-Mutated Advanced Lung Cancer.
The names of the study drugs involved in this study are Niraparib and Osimertinib.